The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...

I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal ...

So this looked at patients with ER-positive, HER2-Positive metastatic breast cancer who had received induction chemotherapy ...

AI is transforming oncology by improving early detection, diagnosis, and treatment personalization through advanced data ...